InvestorsHub Logo
Followers 20
Posts 2617
Boards Moderated 0
Alias Born 01/27/2022

Re: newman2021 post# 405269

Wednesday, 03/08/2023 11:14:03 AM

Wednesday, March 08, 2023 11:14:03 AM

Post# of 426447
newman, I also think Pfizer has brass balls when it comes to marketing, which could play to Vascepa's favor. It's a perfect drug, virtually no side-effects, very safe. And even if it's efficacy is modest for some and fantastic for others, we know that EPA is a net positive for virtually anyone that takes it. You just listen to the stories - people take it for their heart, but their skin clears up, their arthritis is subdued, inflammation recedes, ......

It positively impacts virtually everything that is affected by inflammation - which we now know causes virtually all of our major body ailments.

My point is, I think a company like Pfizer can take advantage of this with their marketing muscle.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News